Nuvectis Pharma, Inc. (NVCT)
NASDAQ: NVCT · Real-Time Price · USD
19.84
-0.45 (-2.22%)
At close: Nov 19, 2026, 4:00 PM EST
20.40
+0.56 (2.82%)
After-hours: Nov 19, 2026, 5:16 PM EST
Nuvectis Pharma Employees
Nuvectis Pharma had 19 employees as of September 30, 2026. The number of employees increased by 6 or 46.15% compared to the same quarter last year. That makes Nuvectis Pharma the 38,618th largest employer in the world and 5,544th in the United States.
Employees
19
Change (1Y)
6
Growth (1Y)
46.15%
Revenue / Employee
n/a
Profits / Employee
-$2,655,474
Market Cap
682.28M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2026 | 19 | 6 | 46.15% |
| Jun 30, 2026 | 16 | 3 | 23.08% |
| Mar 31, 2026 | 12 | -1 | -7.69% |
| Dec 31, 2025 | 13 | 0 | - |
| Sep 30, 2025 | 13 | 0 | - |
| Jun 30, 2025 | 13 | 0 | - |
| Mar 31, 2025 | 13 | 0 | - |
| Dec 31, 2024 | 13 | 0 | - |
| Sep 30, 2024 | 13 | 0 | - |
| Jun 30, 2024 | 13 | - | - |
| Dec 31, 2023 | 13 | 2 | 18.18% |
| Dec 31, 2022 | 11 | 3 | 37.50% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Kura Oncology | 260 |
| Prime Medicine | 146 |
| Solid Biosciences | 121 |
| Aura Biosciences | 113 |
| Annexon | 97 |
| OmniAb | 89 |
| Apnimed | 81 |
| Achieve Life Sciences | 28 |
NVCT News
- 15 days ago - Nuvectis Pharma Earnings Call Transcript: Q3 2026 - Transcripts
- 15 days ago - Nuvectis Pharma Earnings release: Q3 2026 - Filings
- 15 days ago - Nuvectis Pharma Quarterly report: Q3 2026 - Filings
- 15 days ago - Nuvectis Pharma Reports Third Quarter 2026 Financial Results and Business Highlights - GlobeNewsWire
- 17 days ago - Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026 - GlobeNewsWire
- 17 days ago - Nuvectis Pharma Slides: Corporate presentation - Filings
- 24 days ago - Nuvectis Pharma’s NXP200 shows positive Phase 1b results in gliomas - TheFly
- 24 days ago - Nuvectis Reports Positive Data from NXP200 Phase 1b Study Demonstrating Durable Responses, Including Complete Responses, in BRAF V600-mutated Recurrent or Progressive Gliomas - GlobeNewsWire